Soticlestat (TAK-935)

Takeda Pharmaceuticals

Cholesterol 24-hydroxylase (CH24H) Inhibitor Soticlestat exerts its potential effects via the inhibition of Cholesterol 24-hydroxylase (CH24H). CH24H converts cholesterol to 24S-hydroxycholesterol (24HC) in the brain. Reduction of 24HC has been shown to reduce glutamatergic signaling and inflammation, which may have downstream effects on seizure susceptibility.

Developmental Epileptic Encephalopathies / Dravet syndrome and Lennox-Gastaut syndrome

United States, Australia, Belgium, Canada, China, France, Greece, Hungary, Italy, Japan, Latvia, the Netherlands, Poland, Serbia, Spain, Ukraine*, Russia*

*No current active recruitment in these countries